A prescription solves one part of the problem. It doesn’t teach someone how to eat differently or build habits that make a change last, and it doesn’t address the stress that shaped their relationship with food in the first place. That gap is becoming a real budget conversation for employers, not just a health one.

Employer spending on GLP-1 drugs has doubled in a single year, rising from $11 to $24 per member per month. GLP-1s now account for 10.5% of all prescription drug claims, up from 6.9% in 2023. Whatever the exact number looks like at any given organization, benefits leaders are already feeling the shift. The conversation is no longer just about whether to cover these medications. It’s about what happens around them. 

Why GLP-1 Cost Pressure Is Reshaping Benefits Conversations 

Employer health benefit costs are already rising faster than they have in years, and GLP-1 spending is a meaningful part of that pressure. Bank of America’s CEO recently noted that the company now spends more than $250 million a year on GLP-1 drugs for its roughly 211,000 employees, up from zero five years ago. That spending now makes up about 13% of the company’s $2 billion annual healthcare budget. For many organizations, this is the first time a single category of prescription drug has moved a benefits budget enough to prompt a board-level conversation. 

That pressure is pushing HR and finance teams to ask a sharper question than “do we cover this.” They’re asking whether coverage alone is enough, or whether the investment needs support built around it to actually pay off. 

What GLP-1s Do, and Don’t, Solve on Their Own 

GLP-1 medications can be an effective tool for the specific conditions they are prescribed to treat, and that is a decision between an employee and their physician, not something LifeSpeak should weigh in on clinically. 

What is clearer from an employer’s vantage point is that a prescription does not automatically come with the behavior-change support that determines whether results are sustained. Long-term success with any weight or metabolic health intervention typically depends on nutrition habits, physical activity, sleep, and stress management working alongside it, not instead of it. Employees starting a GLP-1 regimen are often left to figure out that supporting structure on their own, at exactly the point when guidance would matter most. 

The Behavior-Change Support Gap Employers Are Discovering 

This is where the wellbeing conversation and the pharmacy conversation start to overlap. An employer that only covers the medication is paying for one piece of a bigger picture. An employer that also makes it easy for employees to access nutrition coaching, sustainable fitness habits, and mental health support around that transition is investing in the piece that determines whether the first piece holds up. 

That is not a new idea for LifeSpeak. It is the same logic behind an integrated approach to any single-condition benefit: a point solution addressing one part of a person’s health, in isolation from the rest of their life, tends to underperform relative to support that treats those pieces as connected. 

What This Means for Benefits Strategy 

For HR and benefits leaders, the practical question is less about GLP-1 policy specifically and more about whether existing wellness infrastructure is built to support employees through a major health transition, whatever triggers it. Nutrition guidance, coaching, and mental health support that already exist as part of a broader wellness offering can extend naturally to employees navigating a GLP-1 regimen, without requiring a new, separate benefit built just for this purpose. 

Employers evaluating this now are effectively asking the same question that applies across the rest of workforce wellbeing: is support integrated enough to meet people where they actually are, or is it one more disconnected piece for an employee to manage alone.

What’s Next

Learn more about LifeSpeak’s Fitness & Nutrition wellness track.